Treatment of heart disease by disruption of the anchoring of PP2A
AssigneesUniversity of Miami, The Board of Trustees of the Leland Stanford Junior University
InventorsMichael S. Kapiloff, Jinliang Li
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPβ. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPβ to which PP2A binds.
Claims10
A composition comprising a nucleic acid that encodes a molecule consisting of amino acids 2132-2319 of human mAKAP, wherein said molecule inhibits the-dephosphorylation activity of protein (serine-threonine) phosphatase 2A (PP2A) resulting in a maintained level of phosphorylation on serum response factor (SRF).
A method of treating heart failure with reduced ejection fraction, comprising administering to cardiac cells of a patient in need thereof, a therapeutically effective amount of a composition comprising a nucleic acid that encodes a molecule consisting of amino acids 2132-2319 of human mAKAP, wherein said molecule inhibits the dephosphorylation activity of protein (serine-threonine) phosphatase 2A (PP2A) resulting in a maintained level of phosphorylation on serum response factor (SRF).
Dependencies are inferred from the claim text.